CTEV
Claritev CorporationNYSEHealthcare$17.46+3.74%ClosedMarket Cap: $289.0M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-1.61
P/S
0.29
EV/EBITDA
10.30
DCF Value
$131.88
FCF Yield
-4.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
27.6%
Operating Margin
4.7%
Net Margin
-29.4%
ROE
378.0%
ROA
-5.8%
ROIC
0.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $246.6M | -109.1% | $8.7M | $-80.6M | $-4.88 | — |
| FY 2025 | $965.4M | 27.6% | $45.1M | $-284.3M | $-17.30 | — |
| Q3 2025 | $246.0M | 74.8% | $10.1M | $-69.8M | $-4.23 | — |
| Q2 2025 | $241.6M | 74.8% | $16.6M | $-62.6M | $-3.81 | — |
| Q1 2025 | $231.3M | 73.9% | $9.7M | $-71.3M | $-4.38 | — |
| Q4 2024 | $232.1M | 75.4% | $-41.4M | $-138.0M | $-8.49 | — |
| FY 2024 | $930.6M | 74.3% | $-1.39B | $-1.65B | $-101.92 | — |
| Q3 2024 | $230.5M | 73.6% | $-338.2M | $-391.4M | $-24.25 | — |
| Q2 2024 | $233.5M | 73.7% | $-523.9M | $-576.7M | $-35.78 | — |
| Q1 2024 | $234.5M | 74.4% | $-486.4M | $-539.7M | $-33.40 | — |
| Q4 2023 | $244.1M | 75.2% | $40.8M | $-31.4M | $-1.95 | — |
| FY 2023 | $961.5M | 75.5% | $162.0M | $-91.7M | $-5.69 | — |